Quantification of hormone receptors to guide adjuvant therapy choice in early breast cancer: Better methods required for improved utility

Journal of Clinical Oncology

Volumn 29, Issue 27, 2011, Pages 3715-3716

  Bartlett, John M S ^a   Rea, Daniel ^b   Rimm, David L ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; DIAGNOSTIC VALUE; DNA DETERMINATION; EARLY CANCER; HEALTH CARE UTILIZATION; HORMONE RELEASE; IMMUNOHISTOCHEMISTRY; LETTER; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; PATIENT SELECTION; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 80053079430     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.3704     Document Type: Letter

References (11)

1. Mackey JR: Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer? J Clin Oncol 29:1504-1506, 2011
2. Bartlett JM, Brookes CL, Robson T, et al: Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: A prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol 29:1531-1538, 2011
3. Van de Velde CJ, Rea D, Seynaeve C, et al: Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial. Lancet 377:321-331, 2011
4. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
5. Dowsett M, Cuzick J, Wale C, et al: Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study. J Clin Oncol 23:7512-7517, 2005 (Pubitemid 46291814)
6. National Institute for Health and Clinical Excellence: NICE Guidance CG80: Breast Cancer (early and locally advanced). February 2009. http://guidance.nice.org.uk/CG80
7. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:E48-E72, 2010
8. Dowsett M, Allred C, Knox J, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059-1065, 2008
9. McCabe A, Dolled-Filhart M, Camp RL, et al: Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 97:1808-1815, 2005 (Pubitemid 43033901)
10. Bartlett JM, Ibrahim M, Jasani B, et al: External quality assurance of HER2 FISH and ISH testing: Three years of the UK national external quality assurance scheme. Am J Clin Pathol 131:106-111, 2009
11. Miller KD, Ibrahim M, Barnett S, et al: Technical aspects of predictive and prognostic markers in breast cancer: What UKNEQAS data shows. Curr Diagn Pathol 13:135-149, 2007 (Pubitemid 46518122)